For patients of Group 2 (CTLA-4high tumor cells, densityhigh CTLA-4+ lymphocytes), high levels of soluble CTLA-4 in the tumor microenvironment would suppress TIL anti-tumor immunity to no stronger than that of the densitylow groups, which would lead to poor prognosis. Here, CTLA4 is linked to neoplasm.